Jennifer Champoux
Chief Operating Officer at MONTE ROSA THERAPEUTICS, INC.
Profile
Jennifer Champoux currently works at Monte Rosa Therapeutics, Inc., as Chief Operating & People Officer from 2021.
Ms. Champoux also formerly worked at H3 Biomedicine, Inc., as Executive Director-Operations.
Ms. Champoux received her graduate degree from Indiana University.
Jennifer Champoux active positions
| Companies | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Chief Operating Officer | 2021-02-28 |
Former positions of Jennifer Champoux
| Companies | Position | End |
|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - |
Training of Jennifer Champoux
| Indiana University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Stock Market
- Insiders
- Jennifer Champoux